The MPap DNA Methylation Test is an in vitro diagnostic reagent for endometrial cancer detection. For women atover 40 years of age with abnormal uterine bleeding, the methylation status of BHLHE22CDO1 genes from conventional Pap smear, can be used as an auxiliary diagnosis of endometrial cancer. The test result provides an important triage for further invasive endometrial biopsy, which will substantially reduce the need of invasive proceduresincrease the feasibility of endometrial cancer screening in high risk populations. This is a ground breaking test.

EPICAn is a novel technique that uses liquid biopsy for epigenetic analysis. Using methylation-specific PCR method to analyze specific gene methylation of cell-free DNA in plasma for early detection of breast cancer. The advantages of this technology are 1. High accuracy 2. Low false positive rate 3. Low-invasive 4. less limitation 5. Available for routine continuous detection 6. Monitoring cancer changes 7. Aided diagnosis 8. Automated process 9. Easy-to-operate 10. Rapid analysis. It is expected that EPICAn technique can increase the accuracy of early detection of breast canceraid clinicians diagnosis.

SeraParma™ COVID-19 IgM rapid test has high detection sensitivity, which can provide rapid detection of early COVID-19 infection. This SeraParma™ COVID-19 IgM rapid test can detect whether there are IgM antibodies produced in the early stage of infection (within 7 days of symptoms onset) with one drop of the specimen (serumfingertip blood) in 15 minutes by naked eyes compared with LFIA antibody rapid test. It is worth noting that the SeraParma™ COVID-19 IgM rapid test can accurately detect the patients with positive infection within 7 days of the onset of symptoms compared with LFIA.